EW Healthcare Partners Announces Acquisition of Germfree Laboratories, Inc.
October 18, 2022 12:46 ET
|
EW Healthcare Partners
NEW YORK and ORMAND BEACH, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- EW Healthcare Partners announced today that it has acquired Germfree Laboratories, Inc., a leading U.S. manufacturer of turnkey,...
EW Healthcare Partners Acquires Germfree Laboratories, Inc.
October 18, 2022 12:16 ET
|
EW Healthcare Partners
NEW YORK and ORMAND BEACH, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- EW Healthcare Partners announced today that it has acquired Germfree Laboratories, Inc., a leading U.S. manufacturer of turnkey,...
Helena Strigård appointed as new CEO of rapidly expanding NorthX Biologics
September 20, 2022 01:00 ET
|
NorthX Biologics Matfors AB
MATFORS, Sweden, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The Board of NorthX Biologics ("NorthX") has appointed Helena Strigård as the new CEO. She joins NorthX from her role as Director General for the...
Helena Strigård ny vd för snabbt expanderande NorthX Biologics
September 20, 2022 01:00 ET
|
NorthX Biologics Matfors AB
MATFORS, Sweden, Sept. 20, 2022 (GLOBE NEWSWIRE) -- NorthX Biologics (“NorthX”) styrelse har utsett Helena Strigård till ny vd. Hon kommer närmast från rollen som vd för branschorganisationen...
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
June 12, 2022 05:30 ET
|
Novartis Pharma AG
In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than...
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
May 27, 2022 18:58 ET
|
Novartis Pharma AG
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah...
AGC Biologics Invests in New Viral Vector Suspension Capabilities at U.S. Cell & Gene Hub
May 17, 2022 22:03 ET
|
AGC Biologics
SEATTLE, May 17, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector...
Cell and Gene Therapy Market Size, Growth, Trends [2022] | Global Industry Share, Key Players, Recent Developments, Type & Application, Challenges & Restraints, Revenue, Stakeholders and Forecast Research | Market Reports World
May 09, 2022 01:36 ET
|
Market Reports World
Pune, May 09, 2022 (GLOBE NEWSWIRE) -- Global Cell and Gene Therapy Market Size 2022 research report provides an in-depth analysis of market size, share, growth, trends, and forecast. The Cell and...
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
March 25, 2022 08:03 ET
|
Novartis Pharma AG
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial...
Almac Pharma Services Expands Its Unique Ultra-Low Temperature Solutions for Advanced Therapy Medicinal Products
March 14, 2022 12:31 ET
|
Almac Group
CRAIGAVON, Northern Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Almac Pharma Services, a member of the Almac Group providing innovative pharmaceutical development, manufacture and commercial...